MedPath

Differential responses to Cognitive Behavioural Analysis System of Psychotherapy (CBASP) versus escitalopram in chronic major depression with and without early trauma

Conditions
Differential responses to Cognitive Behavioural Analysis System of Psychotherapy (CBASP)versus Escitalopram in chronic major depression with and without early trauma.
Registration Number
EUCTR2007-006914-41-DE
Lead Sponsor
Dept. of Psychiaty, University of Freiburg
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

-Chronic MDD according to DSM-IV (modification: depressive symptomatology for at least one year), or recurrent MDE (third or greater episode with the immediately preceeding episode being no more than 2.5 years before the onset of the present episode)
-age 18-65
-score of at least 18 on the Montgomery-Asberg-Rating Scale for Depression (MADRS)

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

-Acute risk for suicide
-history of psychotic symptoms, bipolar disorder or dementia
-Severe substance-related abuse or dependence disorder
-Schizotypal, antisocial or borderline personality disorder
-Serious medical condition
-severe cognitive impairment
-Absence of a response to previous adequate trial of the study medication/CBASP
-Hypersensitivity to escitalopram
-Treatment with a MAO-inhibitor within 1 week before the initiation of study treatment

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: To assess whether in patients with chronic Major Depressive Disorder (MDD) and early life trauma, the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is superior to escitalopram plus Clinical Management in reducing depressive symptoms and leads to higher remission rates.;Secondary Objective: It is important to find effective treatment strategies for chronic depression since it is a common (roughly a third of all depressive disorders take a chronic course) and a particularly disabling disorder which is associated with greater comorbidity, more significant impairments in functioning, increased health care utilisation, and more frequent suicide attempts and hospitalisations than acute major depressive episodes (Arnow et al., J Clin Psychol, 2003). So far, chronic depressions are considered as treatment resistant by most clinicians. Chronically depressed patients account for a major part of the patients requiring hospitalisation;Primary end point(s): MADRS score at week 8.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath